From the 39 patients who were classified as HER2+by immuno-PET, 28 showed objective response on computed tomography (CT) after T-DM1 therapy to give a positive predictive value (PPV) of 72%

From the 39 patients who were classified as HER2+by immuno-PET, 28 showed objective response on computed tomography (CT) after T-DM1 therapy to give a positive predictive value (PPV) of 72%. Furthermore, we discuss how89Zr-immuno-PET may be utilized in future clinical trials as an adjunct tool with novel ADCs to select cancer patients who have the greatest potential to benefit from treatment and improve ADC dosing regimens. Keywords:immuno-PET, antibodydrug conjugates, cancer, molecular imaging, companion diagnostics == AntibodyDrug Conjugates == == An Emerging Class of Cancer Therapeutics == Antibodydrug conjugates (ADCs), also referred to as guided missiles or targeted warheads, are one of the fastest growing classes of cancer therapeutics. Over the past decade, several advances have been made to identify novel targets and improve ADC stability and efficacy. Generation of a successful ADC depends on four main components: the target antigen, antibody, linker, and cytotoxic payload (Physique 1).1These immunoconjugates utilize highly specific monoclonal antibodies (mAbs) to deliver extremely potent cytotoxins (ie, subnanomolar half maximal inhibitory concentration values) to the tumor site through antigen targets that are enriched around the cancer cell surface.2,3A covalent linker couples the cytotoxin to the mAb, providing stability and safety during systemic circulation by conferring a therapeutic index to the cytotoxin and limiting off-target effects.3 == Determine 1. == Critical components that influence ADC therapeutics. ADCs consist of a cytotoxic drug conjugated to a mAb via a select linker at choice attachment sites. These components all affect ADC efficacy and safety, and their optimization is essential for successful development (adapted from Panowski et al).1 To date, there are four ADCs that have gained regulatory approval by the US Food and Drug Association (FDA) for cancer treatment. Gemtuzumab ozogamicin developed by Wyeth was the first ADC approved in 2000 for the treatment of CD33+acute myeloid leukemia.4However, it was voluntarily withdrawn from the market in 2010 2010 due to dose-related toxicity but, after a postapproval study, was reintroduced into the market by Pfizer in 2017. In 2011, brentuximab vedotin (Adcentis, Seattle Genetics), which targets CD30, was approved for the treatment of anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma,5followed by approval of trastuzumab emtansine (T-DM1, Roche) in 2013 for the treatment of human epidermal growth factor receptor 2 (HER2)+metastatic breast cancer6and inotuzumab ozogamicin (Pfizer) for the treatment of CD22+relapsed or refractory B-cell precursor acute lymphoblastic leukemia in 2017.7There are currently more than 60 ADCs in clinical trials and several more at the preclinical stage for the treatment of hematological malignancies and solid tumors.8,9 == Target Antigen and Antibody Selection == An important consideration in the development of successful ADCs for cancer treatment is the identification of valid antigens for mAb generation and therapeutic targeting. Acceptable antigens must have (1) high expression in tumors with minimal to no expression in normal tissues, (2) localized expression around the tumor cell surface Dimethylenastron for accessibility to circulating mAbs, and (3) the ability to undergo internalization for transport into the tumor cell followed by intracellular trafficking for processing and payload release3(Physique 2). Among the different target antigens being evaluated in preclinical and clinical trials, a number of them are directed against a specific solid tumor type such as carcinoembryonic antigen-related cell adhesion molecule 5 for metastatic colon cancer,10whereas others are directed against several tumor types (eg, mesothelin [MSLN] and delta-like 3)11-13or against blood cancers (eg, CD37).14ADCs are also being developed to target tumor microenvironment proteins such as transmembrane 4 L6 family member 115and cancer stem cell Dimethylenastron targets including leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5).16,17Interestingly, ADC technology is also being evaluated for nononcologic indications including the delivery of antibiotics conjugated to Dimethylenastron an anti-Staphylococcus aureusmAb to treat infection,18and the delivery of the tyrosine kinase inhibitor dasatinib to T lymphocytes via a chemokine receptor type 4-targeted mAb to repress T cell C3orf29 activation.19 == Determine 2. == Targeted delivery of cytotoxic drugs to cancer cells by ADCs. The ADC selectively binds a cell-surface tumor antigen, resulting in internalization of the ADCantigen complex via endocytosis. The ADCantigen complex then traffics to lysosomal compartments and is degraded to release active cytotoxic drug inside the cell, resulting in cancer cell death (adapted from Panowski et al).1 The antibody selected for ADC development is a major determinant of efficacy and toxicity in vivo. In order to maximize the therapeutic index of an ADC, the antibody must have high specificity for the target antigen while exhibiting low uptake in normal tissues or cross-reactivity with other nonspecific antigens that can result in toxicity or faster rate of clearance.20,21The minimum threshold of expression.